<DOC>
	<DOCNO>NCT00737009</DOCNO>
	<brief_summary>The purpose study describe adherence anastrozole treatment current practice : case anastrozole treatment halt ( timescale cause ) estimate proportion postmenopausal woman early breast cancer continue anastrozole therapy one year follow-up .</brief_summary>
	<brief_title>An Observational Study Adherence Anastrozole Early Breast Cancer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal woman early breast cancer prescribe anastrozole adjuvant endocrine therapy routine clinical practice . Histologically cytologically proven HR+ ( ER PR + ) No concomitant endocrine therapy estrogen therapy selective estrogen receptor modulators Provision write informed consent Recurrence breast cancer Known hypersensitivity anastrozole excipients Any severe concomitant condition make undesirable patient participate trial would jeopardize adherence trial protocol : Amenorrhea &lt; 12 month intact uterus ; Previous inclusion present study ; Participation clinical study last 30 daysÂ· Women agree participate program</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>adherence</keyword>
	<keyword>anastrozole</keyword>
	<keyword>post-menopausal woman</keyword>
</DOC>